PRQR ProQR Therapeutics N.V.

5.14
-0.35  -6%
Previous Close 5.49
Open 5.5
Price To Book 2.44
Market Cap 255,692,831
Shares 49,745,687
Volume 391,079
Short Ratio
Av. Daily Volume 233,937
Stock charts supplied by TradingView

NewsSee all news

  1. ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

    QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second

  2. ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

    LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

  3. ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

    Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber's congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate

  4. ProQR to Present at Cowen and Company 40th Annual Health Care Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA

  5. ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

    LEIDEN, Netherlands and CAMBRIDGE, Mass, Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due 1H 2021.
Sepofarsen (QR-110 ) ILLUMINATE
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
QR-010
Cystic Fibrosis
Phase 1/2 interim analysis announced March 26, 2019. Future development to be conducted by Wings Therapeutics.
QR-313
Epidermolysis bullosa
Phase 1/2 data due 2021.
QR-1123
autosomal dominant retinitis pigmentosa (adRP)
Phase 1/2 interim data March 31, 2020. 2/8 patients demonstrated benefit across multiple concordant outcome measures.
QR-421a - STELLAR
Usher Syndrome Type 2

Latest News

  1. ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

    QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second

  2. ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

    LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

  3. ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

    Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber's congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate

  4. ProQR to Present at Cowen and Company 40th Annual Health Care Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA

  5. ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

    LEIDEN, Netherlands and CAMBRIDGE, Mass, Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  6. ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  7. ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  8. ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  9. ProQR to Present at Upcoming Scientific Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  10. ProQR to Present at Upcoming Investor Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  11. ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

    Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123 Investigational New Drug

  12. ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA

  13. ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  14. ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

    Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated with a favorable

  15. ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for

  16. ProQR to Present at Two Investor Conferences in October

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  17. ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the